S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Stock market today: Wall Street clings to modest gains and marks another winning week
Dropbox’s stock is a falling knife worth catching
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Novavax’s dispute resolution and upcoming earnings call
Stock ideas from the 2024 Microcap Conference
The Retirement of Your Dreams Awaits You… (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Warner Bros. Discover: Debt down, profits up, yet questions remain
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Stock market today: Wall Street clings to modest gains and marks another winning week
Dropbox’s stock is a falling knife worth catching
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Novavax’s dispute resolution and upcoming earnings call
Stock ideas from the 2024 Microcap Conference
The Retirement of Your Dreams Awaits You… (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Warner Bros. Discover: Debt down, profits up, yet questions remain
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Stock market today: Wall Street clings to modest gains and marks another winning week
Dropbox’s stock is a falling knife worth catching
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Novavax’s dispute resolution and upcoming earnings call
Stock ideas from the 2024 Microcap Conference
The Retirement of Your Dreams Awaits You… (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Warner Bros. Discover: Debt down, profits up, yet questions remain
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Stock market today: Wall Street clings to modest gains and marks another winning week
Dropbox’s stock is a falling knife worth catching
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024. (Ad)
Novavax’s dispute resolution and upcoming earnings call
Stock ideas from the 2024 Microcap Conference
The Retirement of Your Dreams Awaits You… (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Warner Bros. Discover: Debt down, profits up, yet questions remain

Pro Medicus (PMCUF) Stock Forecast & Price Target

$60.28
0.00 (0.00%)
(As of 02/23/2024 ET)

Pro Medicus Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 3 Analyst Ratings

Analysts' Consensus Price Target

N/A

TypeCurrent Forecast
2/24/23 to 2/24/24
1 Month Ago
1/25/23 to 1/25/24
3 Months Ago
11/26/22 to 11/26/23
1 Year Ago
2/24/22 to 2/24/23
Consensus Rating
Hold
Hold
Hold
Reduce
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
0 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
2 Sell rating(s)
Consensus Price TargetN/AN/AN/AN/A
Predicted UpsideN/AN/AN/AN/A
Get Pro Medicus Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PMCUF and its competitors with MarketBeat's FREE daily newsletter.


PMCUF Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PMCUF Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Pro Medicus Stock vs. The Competition

TypePro MedicusMedical CompaniesS&P 500
Consensus Rating Score
2.33
2.68
2.48
Consensus RatingHoldModerate BuyHold
Predicted Upside2,459.10% Upside7.47% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/27/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy
6/29/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold
3/6/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 02:18 AM ET.












PMCUF Price Target - Frequently Asked Questions

What is Pro Medicus's consensus rating?

According to the issued ratings of 3 analysts in the last year, the consensus rating for Pro Medicus stock is Hold based on the current 2 hold ratings and 1 buy rating for PMCUFthe . Learn more on PMCUF's analyst rating history.

Do Wall Street analysts like Pro Medicus more than its competitors?

Analysts like Pro Medicus less than other Medical companies. The consensus rating for Pro Medicus is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how PMCUF compares to other companies.


Stock Ratings Reports and Tools

This page (OTCMKTS:PMCUF) was last updated on 2/24/2024 by MarketBeat.com Staff